Diane Golebiowski

Diane Golebiowski, PhD has extensive experience in gene therapy and vector biology. Diane currently serves as the Director of AAV Platform Development at Oxford Biomedica Solutions since January 2023, and previously held the role of Associate Director at the same company from March 2022 to January 2023.

Prior to joining Oxford Biomedica Solutions, Diane worked at Homology Medicines, Inc. as the Associate Director of AAV Platform Development from July 2020 to March 2022. In this role, they led a team to engineer a next generation AAV vector production platform, collaborated with research and process development teams, and designed novel plasmids for AAV vector production.

Before their time at Homology Medicines, Diane served as a Principal Scientist in Vector Biology at Solid Biosciences from January 2019 to July 2020. Their responsibilities included advancing gene therapy drug development programs, exploring ways to modulate the immune system for enhanced gene therapy, and improving AAV manufacturing platforms.

Diane's work experience also includes roles as a Senior Research Scientist and a Research Scientist at Solid Biosciences, where they contributed to gene therapy drug development programs and explored AAV manufacturing platforms. Additionally, they have served as a Senior Research Technician at the Dana-Farber Cancer Institute and as a Research Assistant at Ithaca College.

Diane earned their PhD from UMass Medical School, where they focused on research in the laboratory of Dr. Miguel Sena-Esteves. Diane also worked as a Senior Research Technician at the Dana-Farber Cancer Institute under the supervision of Dr. Charles Stiles during their earlier career. Diane began gaining research experience as a Research Assistant at Ithaca College under the supervision of Dr. Vicki Cameron.

Diane Golebiowski, PhD, has a Bachelor of Arts (B.A.) degree in Biology from Ithaca College. Diane also holds a Ph.D. in Biology and Biomedical Sciences from UMass Chan Medical School. In addition, they have completed a Mini-MBA in The Business of Biopharma from Bentley University.